XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.67

-10.7%

Jan 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (10425)	6/13/1999 8:37:00 PM
From: Robert S.	Read Replies (1) of 17367

RobertK, over the last several months I have referenced numerous studies that presented contradictory evidence pertaining to endotoxins. I readily admit that the preponderance of research does support the role endotoxins play in many maladies. This does not necessitate that the minority view is incorrect. Time will tell. The endotoxin paper does present a promising outlook for BPI-based therapies. I think we can all agree that the sooner this treatment is administered, the better off the patient will fare. This question remains: How soon is soon enough? Edward Paule recently posed interesting questions that received no response. Message 10069128 Perhaps you can shed light upon Ed's questions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next